- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05656560
Reduzindo a polifarmácia geriátrica de alto risco por meio do EHR Nudges R01 Trial (HRPP)
Reduzindo a Polifarmácia de Alto Risco Usando a Economia Comportamental por meio de Registros Eletrônicos de Saúde
High-risk polypharmacy is common among older adults in the United States, is particularly dangerous for individuals with dementia or cognitive impairment, and is associated with harms such as adverse drug reactions, falls, and higher costs of care. This project aims to test in a pragmatic clinic-randomized controlled trial two electronic health record-based behavioral economic nudges to help clinicians reduce high-risk polypharmacy among their older adult patients and in the subgroup with dementia or cognitive impairment.
The main questions this trial aims to answer are:
Aim 1: To evaluate the effects of an EHR-based commitment nudge, a justification nudge, and the combination of both nudges on a composite measure of high-risk polypharmacy via a pragmatic randomized controlled trial. The investigators will use cluster randomization in which primary care clinics are randomized to receive 0, 1, or 2 nudges using a factorial design. The nudges will run for 18 months, followed by 12 months of observation to assess persistence of effects.
Aim 2: To qualitatively and quantitatively assess clinician experiences with the EHR-based nudges, including their acceptability and effects on workflow. At the conclusion of the intervention period, the investigators will perform semi-structured interviews and field a clinician survey.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- UPMC
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Northwestern Medicine or UPMC primary care clinic: Internal Medicine, Family Medicine, or General Practice or Geriatrics
Exclusion Criteria:
- None
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Clinician education only
Online clinician education |
Brief, online education module for primary care clinicians |
|
Experimental: Commitment nudge
The commitment nudge will be an EHR alert that is triggered when a clinician renews or orders a qualifying medication in any Epic encounter (including non-face-to-face encounters) for a patient aged 65 or greater who meets criteria for high-risk polypharmacy. When triggered, the commitment nudge will offer the clinician a choice option that sets a reminder to discuss polypharmacy at the patient's next visit date. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
Outros nomes:
|
|
Experimental: Justification nudge
The justification nudge will be an EHR alert triggered for patients with high-risk polypharmacy when a clinician begins to renew or newly prescribe a medication that causes a high-risk criterion to be fulfilled (i.e., a medication meeting causing 1 of the 7 high-risk polypharmacy criteria/primary study measures to be met). This alert will inform the clinician of the high-risk nature of the prescription and request a free-text justification for starting or renewing the medication. This written justification will appear in the EHR in a section of that encounter that other EHR users can see. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician rational for high risk polypharmacy
Outros nomes:
|
|
Experimental: Commitment nudge + Justification nudge
This study arm will receive both the commitment nudge and the justification nudge. |
Brief, online education module for primary care clinicians EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
Outros nomes:
EHR clinical decision support alerts-clinician rational for high risk polypharmacy
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The percentage of HRPP with any (1 or more) of the 7 measures of high risk polypharmacy. (Composite measure)
Prazo: 18 months
|
The composite of the 7 high-risk polypharmacy measures (Secondary outcomes #6-12) |
18 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The rate of Emergency Department visits per patient -all cause
Prazo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an emergency department encounter during the look back period. |
18 months
|
|
The rate of Emergency Department visits per patient-Adverse drug event (ADE)-specific
Prazo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an emergency department encounter for ADE during the look back period. |
18 months
|
|
The rate of hospital admissions per patient-all cause
Prazo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an inpatient admission for any reason during the look back period. |
18 months
|
|
The rate of hospital admissions per patient-ADE-specific
Prazo: 18 months
|
Denominator: All older adults with HRPP. Numerator: Patients with an inpatient admission for ADE during the look back period. |
18 months
|
|
The percentage of HRPP patients with a fall condition-drug interaction
Prazo: 18 months
|
Denominator: All older adult patients with HRPP with a fall marker. Numerator: Patients with an active eligible fall risk medication on medication list. |
18 months
|
|
The percentage of HRPP patients with a fall drug-drug interaction
Prazo: 18 months
|
Denominator: All older adult patients with HRPP. Numerator: Patients with greater than or equal to 3 active eligible fall risk medications. |
18 months
|
|
The percentage of HRPP patients with Heart failure-NSAID interaction
Prazo: 18 months
|
Denominator: All older adult patients with HRPP with a CHF marker. Numerator: Patients with an active eligible NSAID medication. |
18 months
|
|
The percentage of HRPP patients with Heart Failure-thiazolidinedione interaction
Prazo: 18 months
|
Denominator: All older adults with HRPP with a CHF marker. Numerator: Patients with an active eligible thiazolidinedione medication. |
18 months
|
|
The percentage of HRPP patients with Heart failure with reduced ejection fraction- non-dihydropyridine calcium channel blocker interaction
Prazo: 18 months
|
Denominator: All older adults with HRPP with CHFlowEF marker. Numerator: Patients with an active eligible calcium channel blocker medication. |
18 months
|
|
The percentage of HRPP patients with CKD-glyburide/glimepiride interaction
Prazo: 18 months
|
Denominator: All older adults with HRPP with most-recent eGFR <60. Numerator: Patients with an active eligible glyburide-containing medication. |
18 months
|
|
The percentage of HRPP patients with CKD-NSAID interaction
Prazo: 18 months
|
Denominator: All older adults with HRPP with most-recent eGFR < 30. Numerator: Patients with an active eligible NSAID medication. |
18 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The percentage of HRPP patients with a hospitalization or emergency department (ED) visit for seizure.
Prazo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines and anticonvulsants |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for pain.
Prazo: 18 months
|
Safety measure for discontinuing or reducing tricyclic antidepressants, gabapentinoids, serotonin and norepinephrine reuptake inhibitors, opioids, and NSAIDs |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for depression or suicidality
Prazo: 18 months
|
Safety measure for discontinuing or reducing tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for anxiety.
Prazo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines, serotonin and norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for sedative withdrawal.
Prazo: 18 months
|
Safety measure for discontinuing or reducing benzodiazepines and Z-drugs (GABA receptor modulators) |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for opioid withdrawal.
Prazo: 18 months
|
Safety measure for discontinuing or reducing opioids |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for behavioral disturbance in dementia or psychosis.
Prazo: 18 months
|
Safety measure for discontinuing or reducing antipsychotics |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for hyperglycemia.
Prazo: 18 months
|
Safety measure for discontinuing or reducing glyburide, glimepiride, and thiazolidinediones |
18 months
|
|
The percentage of HRPP patients with a hospitalization or ED visit for tachycardia (other than ventricular) or hypertensive emergency.
Prazo: 18 months
|
Safety measure for discontinuing or reducing non-dihydropyridine calcium channel blockers |
18 months
|
Colaboradores e Investigadores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- STU00213231
- R01AG070054 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .